CytoDyn (CYDY) EBITDA Margin (2021 - 2022)
CytoDyn (CYDY) recorded EBITDA Margin of -232129.41% in fiscal Q4 2022 (quarter ended May 31, 2022).
Powered by 
Analysis
CytoDyn (CYDY) EBITDA Margin (2021 - 2022) Analysis & Trends
For FY2022 (ended May 31, 2022), CytoDyn reported EBITDA Margin of -48207.67%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 39.10% |
| 10 | CytoDyn | 274.70 Mn | 274.70 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2022 | -232,129.41% |
| Nov 30, 2021 | -11,142.22% |
| Aug 31, 2021 | -52,100.00% |
API Access
CytoDyn EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CYDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CYDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();